article thumbnail

Granules India presented with the Golden Peacock Award for sustainability

Express Pharma

This award was presented at the Institute of Directors’ Annual Global Convention on Corporate Governance and Sustainability being held in London, UK. The post Granules India presented with the Golden Peacock Award for sustainability appeared first on Express Pharma.

102
102
article thumbnail

Opinion: Blood-based biomarkers for Alzheimer’s present complex challenges to health care system

STAT

During an annual checkup, the patient says: “Doc, I saw a commercial about a blood test that can tell if I’ll develop Alzheimer’s. I watched my mother go through it. I want to get tested.” ” He’s referring to the new Alzheimer’s blood-based biomarkers.

301
301
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH Annual Meeting

Express Pharma

New York-based Ichnos Glenmark Innovation (IGI), a clinical-stage biotech company focused on multispecifics in oncology, announced plans to present initial data from its Phase 1 study of ISB 2001 at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

103
103
article thumbnail

STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present

STAT

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published high-impact papers.

351
351
article thumbnail

Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar

Big Molecule Watch

On October 22, 2024, Alvotech and Teva announced that SELARSDI (ustekinumab-aekn) received FDA approval for a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. We previously reported that SELARSDI was approved by the FDA for 45 mg/0.5 launch of SELARSDI approaches in early 2025.”

article thumbnail

Suven to present results from Phase-2a study of Ropanicant at Neuroscience 2024

Express Pharma

Suven Life Sciences announces five presentations covering clinical and pre-clinical assets from their portfolio of new chemical entities at the upcoming Neuroscience 2024 conference, taking place from October 5 to 9, 2024, in Chicago, Illinois, USA.

Labelling 104
article thumbnail

Dr. McKibbin Presents Poster Session at DIA Global Annual Meeting 2023

Safe Biologics

On June 26th, ASBM Chairman Ralph McKibbin presented a poster at the DIA Global Annual Meeting in Boston, MA. Dr. McKibbin presents the poster findings View Dr. McKibbin’s video walkthrough of the poster Prior ASBM surveys across many specialties revealed that 83% of Canadian, 82% of European, and 69% of U.S.